Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 9:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–112 of 112 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pre-Exposure Prophylaxis of HIV Infection Clear all
Withdrawn Not applicable Interventional

mHealth Facilitated Intervention to Improve HIV Pre-Exposure Prophylaxis Adherence

NCT04990583
View directory record Official record
Conditions
Pre-Exposure Prophylaxis, Telemedicine, Medication Adherence
Interventions
Face-to-Face PrEP Adherence Intervention Based on LifeSteps, Adherence Coaching Facilitated by Carium Adherence App
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 7, 2026, 9:35 PM EDT
Recruiting Not applicable Interventional

Point of Care STI Testing

NCT06844045
View directory record Official record
Conditions
Point of Care STI Testing
Interventions
Gonorrhea/chlamydia Point-of-Care Testing
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
16 Years to 24 Years
Enrollment
6,460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 7, 2026, 9:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Developing a Patient Navigation Intervention for PrEP Continuum of Care Among Young Latino MSM (PrEParate)

NCT04048382
View directory record Official record
Conditions
HIV/AIDS
Interventions
Patient Navigation, Usual Care
Behavioral · Other
Lead sponsor
San Diego State University
Other
Eligibility
18 Years to 29 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 7, 2026, 9:35 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

HIV/STD Risk and PrEP Implementation Messaging Among Gay, Bisexual, and Other Men Who Have Sex With Men

NCT06183502
View directory record Official record
Conditions
Sexually Transmitted Infections, Gay, Pre Exposure Prophylaxis
Interventions
Quantitative survey, HIV and STI testing, Qualitative Assessment
Behavioral · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
675 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
San Diego, California • Atlanta, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 7, 2026, 9:35 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

NCT07044297
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Interventions
MK-8527, FTC/TDF, Placebo to MK-8527, Placebo to FTC/TDF
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older
Enrollment
4,390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 7, 2026, 9:35 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

NCT02720094
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir Oral Tablet, TDF/FTC tablets, Placebo for TDF/FTC tablets, Placebo for cabotegravir oral tablet, CAB LA, Placebo for CAB LA
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4,570 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 7, 2026, 9:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Life Steps for PrEP for Youth

NCT03805451
View directory record Official record
Conditions
HIV, Pre-exposure Prophylaxis, Medication Adherence
Interventions
Life Steps for PrEP for Youth
Behavioral
Lead sponsor
Fenway Community Health
Other
Eligibility
16 Years to 24 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
3
States / cities
Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 7, 2026, 9:35 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)

NCT07047716
View directory record Official record
Conditions
HIV Pre-exposure Prophylaxis
Interventions
Lenacapavir Injection, Lenacapavir Tablet
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years and older
Enrollment
339 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
31
States / cities
Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 7, 2026, 9:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Latino MSM Focused Pre-Exposure Prophylaxis Uptake Intervention

NCT05434390
View directory record Official record
Conditions
HIV
Interventions
Estoy PrEParado/ I am PrEPared intervention, Usual Care
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Male only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 7, 2026, 9:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

PrEP, Lube, and the Rectal Mucosa in MSM at Risk of HIV

NCT02401230
View directory record Official record
Conditions
HIV
Interventions
Truvada, Gel lubricant
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 7, 2026, 9:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

NCT02076178
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
744 Tablet, 744 LA Injection, Placebo Tablet, Placebo Injection
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2017 · Synced Oct 7, 2026, 9:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Optimizing PrEP Utilization Among Alcohol and Other Drug (AOD) Using Women of Color

NCT04018651
View directory record Official record
Conditions
HIV Prevention
Interventions
PrEP Master Adherence Intervention
Behavioral
Lead sponsor
Florida International University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
North Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 7, 2026, 9:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis

NCT02165202
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Rilpivirine, Placebo
Drug
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Newark, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 7, 2026, 9:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting.

NCT05867212
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir Injection [Apretude]
Drug
Lead sponsor
Kelley-Ross & Associates, Inc.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 7, 2026, 9:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinician Attitudes and Behaviors Regarding Use of Pre-Exposure Prophylaxis (PrEP) for Primary HIV Prevention

NCT01751659
View directory record Official record
Conditions
Clinician Attitudes About PrEP
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 7, 2026, 9:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PrEPTECH Phase 2 Study of a PrEP Telehealth Intervention

NCT04902820
View directory record Official record
Conditions
Pre-Exposure Prophylaxis, HIV, Telemedicine
Interventions
PrEPTECH website, Online PrEP resource list
Other
Lead sponsor
ETR Associates
Other
Eligibility
15 Years to 27 Years · Male only
Enrollment
229 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Scotts Valley, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 7, 2026, 9:35 PM EDT